JP2002535285A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002535285A5 JP2002535285A5 JP2000594485A JP2000594485A JP2002535285A5 JP 2002535285 A5 JP2002535285 A5 JP 2002535285A5 JP 2000594485 A JP2000594485 A JP 2000594485A JP 2000594485 A JP2000594485 A JP 2000594485A JP 2002535285 A5 JP2002535285 A5 JP 2002535285A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- preparation
- pharmaceutical composition
- inhibiting
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000016605 B-Cell Activating Factor Human genes 0.000 description 13
- 108010028006 B-Cell Activating Factor Proteins 0.000 description 13
- 210000003719 b-lymphocyte Anatomy 0.000 description 13
- 239000012634 fragment Substances 0.000 description 13
- 239000008194 pharmaceutical composition Substances 0.000 description 13
- 230000002401 inhibitory effect Effects 0.000 description 11
- 230000004663 cell proliferation Effects 0.000 description 7
- 208000030289 Lymphoproliferative disease Diseases 0.000 description 6
- 201000001268 lymphoproliferative syndrome Diseases 0.000 description 6
- 230000016784 immunoglobulin production Effects 0.000 description 5
- 208000023275 Autoimmune disease Diseases 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 208000026278 immune system disease Diseases 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000021766 negative regulation of B cell proliferation Effects 0.000 description 1
- 230000005401 negative regulation of immunoglobulin production Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11716999P | 1999-01-25 | 1999-01-25 | |
| US60/117,169 | 1999-01-25 | ||
| US14322899P | 1999-07-09 | 1999-07-09 | |
| US60/143,228 | 1999-07-09 | ||
| PCT/US2000/001788 WO2000043032A2 (en) | 1999-01-25 | 2000-01-25 | Baff, inhibitors thereof and their use in the modulation of b-cell response |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008303135A Division JP4955642B2 (ja) | 1999-01-25 | 2008-11-27 | 免疫応答におけるｂ細胞および免疫グロブリンの刺激および阻害における、ｂａｆｆ、関連するブロック剤およびそれらの使用 |
| JP2012077812A Division JP2012126749A (ja) | 1999-01-25 | 2012-03-29 | 免疫応答におけるｂ細胞および免疫グロブリンの刺激および阻害における、ｂａｆｆ、関連するブロック剤およびそれらの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2002535285A JP2002535285A (ja) | 2002-10-22 |
| JP2002535285A5 true JP2002535285A5 (https=) | 2009-01-22 |
| JP5066314B2 JP5066314B2 (ja) | 2012-11-07 |
Family
ID=26815006
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000594485A Expired - Lifetime JP5066314B2 (ja) | 1999-01-25 | 2000-01-25 | 免疫応答におけるｂ細胞および免疫グロブリンの刺激および阻害における、ｂａｆｆ、関連するブロック剤およびそれらの使用 |
| JP2008303135A Expired - Fee Related JP4955642B2 (ja) | 1999-01-25 | 2008-11-27 | 免疫応答におけるｂ細胞および免疫グロブリンの刺激および阻害における、ｂａｆｆ、関連するブロック剤およびそれらの使用 |
| JP2012012379A Withdrawn JP2012087145A (ja) | 1999-01-25 | 2012-01-24 | 免疫応答におけるｂ細胞および免疫グロブリンの刺激および阻害における、ｂａｆｆ、関連するブロック剤およびそれらの使用 |
| JP2012077812A Pending JP2012126749A (ja) | 1999-01-25 | 2012-03-29 | 免疫応答におけるｂ細胞および免疫グロブリンの刺激および阻害における、ｂａｆｆ、関連するブロック剤およびそれらの使用 |
| JP2014090152A Pending JP2014141527A (ja) | 1999-01-25 | 2014-04-24 | 免疫応答におけるｂ細胞および免疫グロブリンの刺激および阻害における、ｂａｆｆ、関連するブロック剤およびそれらの使用 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008303135A Expired - Fee Related JP4955642B2 (ja) | 1999-01-25 | 2008-11-27 | 免疫応答におけるｂ細胞および免疫グロブリンの刺激および阻害における、ｂａｆｆ、関連するブロック剤およびそれらの使用 |
| JP2012012379A Withdrawn JP2012087145A (ja) | 1999-01-25 | 2012-01-24 | 免疫応答におけるｂ細胞および免疫グロブリンの刺激および阻害における、ｂａｆｆ、関連するブロック剤およびそれらの使用 |
| JP2012077812A Pending JP2012126749A (ja) | 1999-01-25 | 2012-03-29 | 免疫応答におけるｂ細胞および免疫グロブリンの刺激および阻害における、ｂａｆｆ、関連するブロック剤およびそれらの使用 |
| JP2014090152A Pending JP2014141527A (ja) | 1999-01-25 | 2014-04-24 | 免疫応答におけるｂ細胞および免疫グロブリンの刺激および阻害における、ｂａｆｆ、関連するブロック剤およびそれらの使用 |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US6869605B2 (https=) |
| EP (5) | EP2974736A1 (https=) |
| JP (5) | JP5066314B2 (https=) |
| KR (1) | KR100834809B1 (https=) |
| CN (1) | CN100340292C (https=) |
| AT (2) | ATE247482T1 (https=) |
| AU (1) | AU762839B2 (https=) |
| BR (1) | BR0007719A (https=) |
| CA (1) | CA2360062A1 (https=) |
| CY (2) | CY1107453T1 (https=) |
| CZ (1) | CZ299819B6 (https=) |
| DE (1) | DE60004635T2 (https=) |
| DK (2) | DK1146892T3 (https=) |
| EA (1) | EA006108B1 (https=) |
| EE (1) | EE05699B1 (https=) |
| ES (1) | ES2204528T3 (https=) |
| HK (1) | HK1040628B (https=) |
| HU (1) | HUP0105283A3 (https=) |
| IL (3) | IL144202A0 (https=) |
| IS (1) | IS5993A (https=) |
| MX (1) | MXPA01007464A (https=) |
| NO (2) | NO20013641L (https=) |
| NZ (1) | NZ513284A (https=) |
| PL (1) | PL198934B1 (https=) |
| PT (2) | PT1415659E (https=) |
| SI (1) | SI1146892T1 (https=) |
| SK (1) | SK286665B6 (https=) |
| TR (2) | TR200102147T2 (https=) |
| WO (1) | WO2000043032A2 (https=) |
Families Citing this family (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6812327B1 (en) | 1996-10-25 | 2004-11-02 | Human Genome Sciences, Inc. | Neutrokine-alpha polypeptides |
| US20030175208A1 (en) * | 1996-10-25 | 2003-09-18 | Human Genome Sciences, Inc. | Neutrokine-alpha and neutrokine-alpha splice variant |
| US8212004B2 (en) * | 1999-03-02 | 2012-07-03 | Human Genome Sciences, Inc. | Neutrokine-alpha fusion proteins |
| US6689579B1 (en) | 1996-10-25 | 2004-02-10 | Human Genome Sciences, Inc. | Polynucleotides encoding neutrokine-α |
| EP0878552A1 (en) | 1997-05-13 | 1998-11-18 | Erasmus Universiteit Rotterdam | Molecular detection of chromosome aberrations |
| JP2002513587A (ja) | 1998-05-04 | 2002-05-14 | ダコ エー エス | 染色体異常を検出するための方法およびプローブ |
| GB9828628D0 (en) | 1998-12-23 | 1999-02-17 | Glaxo Group Ltd | Novel ligand |
| US7833529B1 (en) | 1999-01-07 | 2010-11-16 | Zymogenetics, Inc. | Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor |
| BR0007719A (pt) * | 1999-01-25 | 2001-11-13 | Biogen Inc | Baff, agentes de bloqueio relacionados e uso dosmesmos no estìmulo e na inibição de células b e deimunoglobulinas em respostas imunológicas |
| US20050100548A1 (en) * | 2001-07-24 | 2005-05-12 | Biogen Idec Ma Inc. | BAFF, inhibitors thereof and their use in the modulation of B-cell response |
| US20030095967A1 (en) | 1999-01-25 | 2003-05-22 | Mackay Fabienne | BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders |
| WO2000068378A1 (en) * | 1999-05-06 | 2000-11-16 | National Jewish Medical And Research Center | Tall-1 nucleic acid molecules, proteins, receptors and methods of use thereof |
| UA75049C2 (uk) * | 1999-08-17 | 2006-03-15 | Байоджен Айдек Ма Інк. | Фармацевтична композиція, що містить поліпептид, який являє собою білковий фактор дозрівання в-клітин (всма), що зв'язується з фактором активації в-клітин (baff), спосіб інгібування росту в-клітин, спосіб лікування аутоімунного захворювання, спосіб лікування гіпертонії, спосіб інгібування запалення та спосіб модулювання імунної відповіді у ссавця за допомогою всма |
| UA74798C2 (uk) | 1999-10-06 | 2006-02-15 | Байоджен Айдек Ма Інк. | Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами |
| CA2396793A1 (en) * | 2000-02-16 | 2001-08-23 | Genentech, Inc. | Uses of agonists and antagonists to modulate activity of tnf-related molecules |
| US7220840B2 (en) | 2000-06-16 | 2007-05-22 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to B lymphocyte stimulator protein |
| AU2001268427B2 (en) | 2000-06-16 | 2007-03-29 | Glaxosmithkline Intellectual Property Limited | Antibodies that immunospecifically bind to blys |
| US7879328B2 (en) | 2000-06-16 | 2011-02-01 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to B lymphocyte stimulator |
| CA2418006A1 (en) | 2000-08-18 | 2002-02-28 | Dyax Corp. | Binding polypeptides for b lymphocyte stimulator protein (blys) |
| WO2002016411A2 (en) | 2000-08-18 | 2002-02-28 | Human Genome Sciences, Inc. | Binding polypeptides and methods based thereon |
| UA83458C2 (uk) * | 2000-09-18 | 2008-07-25 | Байоджен Айдек Ма Інк. | Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf) |
| ATE549354T1 (de) * | 2001-05-11 | 2012-03-15 | Amgen Inc | Peptide und damit zusammenhängende an tall-1 bindende moleküle |
| BRPI0209933B8 (pt) | 2001-05-24 | 2021-05-25 | Zymogenetics Inc | proteína de fusão, e, molécula de ácido nucleico |
| BR0211614A (pt) * | 2001-08-03 | 2006-10-31 | Genentech Inc | polipeptìdeo tacis e br3 e empregos dos mesmos |
| AR035119A1 (es) | 2001-08-16 | 2004-04-14 | Lilly Co Eli | Anticuerpos humanos antagonistas anti-htnfsf13b |
| CA2465268A1 (en) | 2001-10-24 | 2003-05-01 | National Jewish Medical And Research Center | Three-dimensional structures of tall-1 and its cognate receptors and modified proteins and methods related thereto |
| AU2003221256A1 (en) * | 2002-02-21 | 2003-09-09 | Biogen Idec Ma Inc. | Use of bcma as an immunoregulatory agent |
| CN1692127A (zh) * | 2002-07-25 | 2005-11-02 | 健泰科生物技术公司 | Taci抗体及其用途 |
| EP2311867A1 (en) | 2002-10-29 | 2011-04-20 | Anaphore, Inc. | Trimeric binding proteins for trimeric cytokines |
| US7553930B2 (en) | 2003-01-06 | 2009-06-30 | Xencor, Inc. | BAFF variants and methods thereof |
| WO2004074511A1 (en) * | 2003-02-21 | 2004-09-02 | Garvan Institute Of Medical Research | Diagnosis and treatment of baff-mediated autoimmune diseases and cancer |
| CA2523776A1 (en) * | 2003-03-07 | 2004-09-23 | Xencor, Inc. | Baff mutants with at least one amino acid substitution and methods of their production |
| WO2004094620A2 (en) | 2003-03-28 | 2004-11-04 | Biogen Idec Ma Inc. | Truncated baff receptors |
| US20050163775A1 (en) * | 2003-06-05 | 2005-07-28 | Genentech, Inc. | Combination therapy for B cell disorders |
| PL1631313T3 (pl) * | 2003-06-05 | 2015-08-31 | Genentech Inc | Terapia skojarzona zaburzeń z komórek B |
| AU2004285455A1 (en) | 2003-10-20 | 2005-05-12 | Biogen Idec Ma Inc. | Therapeutic regimens for BAFF antagonists |
| CA2554526A1 (en) | 2004-01-29 | 2005-08-18 | Genentech, Inc. | Variants of the extracellular domain of bcma and uses thereof |
| WO2006025345A1 (ja) * | 2004-08-31 | 2006-03-09 | Kowa Company, Ltd. | 抗ヒトｂａｆｆ抗体 |
| NZ583905A (en) | 2004-10-13 | 2011-12-22 | Univ Washington | Use of BAFF to Treat Sepsis |
| AU2006209237B2 (en) * | 2005-01-28 | 2010-06-24 | Biogen Ma Inc. | Use of BAFF to treat Th2-mediated conditions |
| JP2008528006A (ja) * | 2005-01-28 | 2008-07-31 | アポロ ライフ サイエンシズ リミテッド | 分子およびそのキメラ分子 |
| BRPI0612947A2 (pt) * | 2005-05-18 | 2010-12-07 | Biogen Idec Inc | método para o tratamento de uma condição fibrótica, método para tratar a fibrose pulmonar, método para tratar a fibrose hepática, método para tratar a fibrose renal, métodos para tratar uma doença fibrótica e método para prevenir uma doença fibrótica |
| EP1922079A2 (en) | 2005-08-09 | 2008-05-21 | ZymoGenetics, Inc. | Methods for the treatment and prevention of abnormal cell proliferation using taci-fusion molecules |
| AU2006278229B2 (en) | 2005-08-09 | 2011-10-27 | Ares Trading S.A. | Methods for treating B-cell malignancies using TACI-Ig fusion molecule |
| US9168286B2 (en) | 2005-10-13 | 2015-10-27 | Human Genome Sciences, Inc. | Methods and compositions for use in treatment of patients with autoantibody positive disease |
| EA015860B1 (ru) * | 2005-10-13 | 2011-12-30 | Хьюман Дженом Сайенсиз, Инк. | Способы лечения аутоиммунных заболеваний при использовании антагониста нейтрокина-альфа |
| WO2007062090A2 (en) | 2005-11-23 | 2007-05-31 | Genentech, Inc. | Methods and compositions related to b cell assays |
| US8211649B2 (en) | 2006-03-31 | 2012-07-03 | Human Genome Sciences, Inc. | Methods of diagnosing and prognosing hodgkin's lymphoma |
| JP2009537563A (ja) | 2006-05-15 | 2009-10-29 | アレス トレーディング ソシエテ アノニム | Ｔａｃｉ融合分子を使用する自己免疫疾患を治療するための方法 |
| WO2010093993A2 (en) * | 2009-02-12 | 2010-08-19 | Human Genome Sciences, Inc. | Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance |
| CN103168039B (zh) * | 2010-03-11 | 2016-08-03 | 吉利德康涅狄格公司 | 咪唑并吡啶类syk抑制剂 |
| WO2013171296A1 (en) | 2012-05-16 | 2013-11-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Diagnostic and treatment of sarcoidosis |
| CZ2012561A3 (cs) * | 2012-08-22 | 2013-10-23 | Masarykova Univerzita | B-bunecný aktivující faktor pro zvýsení sliznicní imunity kojencu a prípravek jej obsahující |
| US9458246B2 (en) | 2013-03-13 | 2016-10-04 | Amgen Inc. | Proteins specific for BAFF and B7RP1 |
| PH12022550138A1 (en) | 2013-03-13 | 2023-03-06 | Amgen Inc | Proteins specific for baff and b7rp1 and uses thereof |
| US9688767B2 (en) | 2013-03-15 | 2017-06-27 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Method of predicting survival time in myocardial infarction patients by measuring BAFF levels |
| KR101493592B1 (ko) | 2013-04-29 | 2015-02-17 | 부산대학교 산학협력단 | Ｓｏｃｓ3 단백질을 이용한 ｂａｆｆ 연관 면역질환 치료제 스크리닝 방법 |
| CA2929846C (en) | 2013-11-19 | 2020-09-15 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized b-cell activating factor gene |
| TWI662037B (zh) | 2013-12-23 | 2019-06-11 | 美商基利科學股份有限公司 | 脾酪胺酸激酶抑制劑 |
| WO2015100246A1 (en) | 2013-12-24 | 2015-07-02 | Ossianix, Inc. | Baff selective binding compounds and related methods |
| WO2016039801A1 (en) | 2014-01-31 | 2016-03-17 | Boehringer Ingelheim International Gmbh | Novel anti-baff antibodies |
| AR104368A1 (es) | 2015-04-03 | 2017-07-19 | Lilly Co Eli | Anticuerpos biespecíficos anti-cd20- / anti-baff |
| EP3313429B1 (en) | 2015-06-19 | 2021-10-06 | University Of Louisville Research Foundation, Inc. | Immunomodulation for the long term prevention and treatment of autoimmune diseases and foreign tissue rejection |
| CN107328620B (zh) * | 2017-06-23 | 2020-06-05 | 浙江普罗亭健康科技有限公司 | 用于流式细胞技术的封闭缓冲液及试剂盒 |
| US20220133788A1 (en) * | 2017-12-19 | 2022-05-05 | The Johns Hopkins University | Baff therapy to promote anti-tumor immunity |
| US20210238295A1 (en) * | 2018-04-26 | 2021-08-05 | University Of Virginia Patent Foundation | Compositions and methods for treating abdominal aortic aneurysm |
| CN113950479A (zh) | 2019-02-22 | 2022-01-18 | 克洛诺斯生物股份有限公司 | 作为syk抑制剂的缩合吡嗪的固体形式 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US5176996A (en) | 1988-12-20 | 1993-01-05 | Baylor College Of Medicine | Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use |
| US5256775A (en) | 1989-06-05 | 1993-10-26 | Gilead Sciences, Inc. | Exonuclease-resistant oligonucleotides |
| US5264564A (en) | 1989-10-24 | 1993-11-23 | Gilead Sciences | Oligonucleotide analogs with novel linkages |
| US5595721A (en) * | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
| DK0897390T3 (da) | 1996-03-14 | 2004-03-08 | Human Genome Sciences Inc | Human tumornekrosefaktor-delta og -epsilon |
| US6541224B2 (en) * | 1996-03-14 | 2003-04-01 | Human Genome Sciences, Inc. | Tumor necrosis factor delta polypeptides |
| ES2248823T5 (es) * | 1996-10-25 | 2011-11-03 | Human Genome Sciences, Inc. | Neutroquina alfa. |
| SE505941C2 (sv) | 1996-10-29 | 1997-10-27 | Bjoern Hellstroem | Klämskyddslist |
| AU5705898A (en) * | 1996-12-17 | 1998-07-15 | Schering Corporation | Mammalian cell surface antigens; related reagents |
| US5969102A (en) * | 1997-03-03 | 1999-10-19 | St. Jude Children's Research Hospital | Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof |
| CA2232743A1 (en) * | 1997-04-02 | 1998-10-02 | Smithkline Beecham Corporation | A tnf homologue, tl5 |
| JP2002517977A (ja) | 1997-06-06 | 2002-06-18 | リジェネロン ファーマシューティカルズ，インコーポレイテッド | Ｔｎｆリガンドファミリーのｎｔｎ−２メンバー |
| IL133315A0 (en) * | 1997-06-06 | 2001-04-30 | Regeneron Pharma | Ntn-2 member of tnf ligand family |
| WO1999011791A2 (en) | 1997-09-05 | 1999-03-11 | University Of Washington | Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents |
| SK3542000A3 (en) | 1997-09-12 | 2000-08-14 | Apotech R & D Sa | Nucleic acid coding ligand april, a vector, a host cell, method for preparing ligand april, a polypeptide of ligand april, a pharmaceutical composition and an antibody, and use thereof |
| CA2303424A1 (en) | 1997-09-12 | 1999-03-18 | Jurg Tschopp | Kay - a novel immune system protein |
| JP2002503444A (ja) | 1997-11-26 | 2002-02-05 | イーライ・リリー・アンド・カンパニー | リガンドファミリー遺伝子 |
| US6297367B1 (en) * | 1997-12-30 | 2001-10-02 | Chiron Corporation | Polynucleotide encoding TNFL1 |
| WO1999033980A2 (en) | 1997-12-30 | 1999-07-08 | Chiron Corporation | Members of tnf and tnfr families |
| AU1467000A (en) | 1998-11-04 | 2000-05-22 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | A novel tumor necrosis factor family member, drl, and related compositions and methods |
| GB9828628D0 (en) | 1998-12-23 | 1999-02-17 | Glaxo Group Ltd | Novel ligand |
| DE60043626D1 (de) | 1999-01-07 | 2010-02-11 | Zymogenetics Inc | Verfahren zur therapeutischen Verwendung von löslichen rezeptoren BR43X2 |
| BR0007719A (pt) | 1999-01-25 | 2001-11-13 | Biogen Inc | Baff, agentes de bloqueio relacionados e uso dosmesmos no estìmulo e na inibição de células b e deimunoglobulinas em respostas imunológicas |
| US6475986B1 (en) | 1999-02-02 | 2002-11-05 | Research Development Foundation | Uses of THANK, a TNF homologue that activates apoptosis |
| NZ513290A (en) | 1999-02-23 | 2004-05-28 | Human Genome Sciences Inc | Neutrokine-alpha and neutrokine-alpha splice variant |
| AU3380200A (en) | 1999-02-24 | 2000-09-14 | General Hospital Corporation, The | Method for cloning signal transduction intermediates |
| WO2000068378A1 (en) | 1999-05-06 | 2000-11-16 | National Jewish Medical And Research Center | Tall-1 nucleic acid molecules, proteins, receptors and methods of use thereof |
| JP2003521931A (ja) * | 2000-02-11 | 2003-07-22 | バイオジェン インコーポレイテッド | Ｔｎｆファミリーの異種ポリペプチド |
| AU2001268427B2 (en) | 2000-06-16 | 2007-03-29 | Glaxosmithkline Intellectual Property Limited | Antibodies that immunospecifically bind to blys |
| EP1309718A4 (en) | 2000-08-15 | 2004-08-25 | Human Genome Sciences Inc | Neutrokine-alpha and neutrokine-alpha splice variant |
| EP1456347A4 (en) | 2001-11-16 | 2006-08-02 | Human Genome Sciences Inc | IMMUNE SPECIFIC TO BLYS BINDING ANTIBODIES |
-
2000
- 2000-01-25 BR BR0007719-4A patent/BR0007719A/pt not_active Application Discontinuation
- 2000-01-25 DE DE60004635T patent/DE60004635T2/de not_active Expired - Fee Related
- 2000-01-25 CA CA002360062A patent/CA2360062A1/en not_active Abandoned
- 2000-01-25 PT PT03018879T patent/PT1415659E/pt unknown
- 2000-01-25 DK DK00909970T patent/DK1146892T3/da active
- 2000-01-25 EP EP15174329.1A patent/EP2974736A1/en not_active Withdrawn
- 2000-01-25 AU AU32142/00A patent/AU762839B2/en not_active Expired
- 2000-01-25 HK HK02102203.7A patent/HK1040628B/en not_active IP Right Cessation
- 2000-01-25 PL PL349772A patent/PL198934B1/pl unknown
- 2000-01-25 CZ CZ20012696A patent/CZ299819B6/cs not_active IP Right Cessation
- 2000-01-25 EE EEP200100386A patent/EE05699B1/xx unknown
- 2000-01-25 TR TR2001/02147T patent/TR200102147T2/xx unknown
- 2000-01-25 EP EP10180420.1A patent/EP2298332B1/en not_active Expired - Lifetime
- 2000-01-25 WO PCT/US2000/001788 patent/WO2000043032A2/en not_active Ceased
- 2000-01-25 EP EP10181337A patent/EP2319527A3/en not_active Ceased
- 2000-01-25 EA EA200100822A patent/EA006108B1/ru not_active IP Right Cessation
- 2000-01-25 ES ES00909970T patent/ES2204528T3/es not_active Expired - Lifetime
- 2000-01-25 IL IL14420200A patent/IL144202A0/xx unknown
- 2000-01-25 SI SI200030207T patent/SI1146892T1/xx unknown
- 2000-01-25 SK SK1044-2001A patent/SK286665B6/sk not_active IP Right Cessation
- 2000-01-25 DK DK03018879.1T patent/DK1415659T3/da active
- 2000-01-25 EP EP00909970A patent/EP1146892B1/en not_active Revoked
- 2000-01-25 HU HU0105283A patent/HUP0105283A3/hu unknown
- 2000-01-25 KR KR1020017009356A patent/KR100834809B1/ko not_active Expired - Lifetime
- 2000-01-25 AT AT00909970T patent/ATE247482T1/de active
- 2000-01-25 NZ NZ513284A patent/NZ513284A/en not_active IP Right Cessation
- 2000-01-25 JP JP2000594485A patent/JP5066314B2/ja not_active Expired - Lifetime
- 2000-01-25 CN CNB008054878A patent/CN100340292C/zh not_active Expired - Lifetime
- 2000-01-25 AT AT03018879T patent/ATE515267T1/de active
- 2000-01-25 MX MXPA01007464A patent/MXPA01007464A/es active IP Right Grant
- 2000-01-25 PT PT00909970T patent/PT1146892E/pt unknown
- 2000-01-25 EP EP03018879A patent/EP1415659B9/en not_active Revoked
-
2001
- 2001-01-25 TR TR2004/03498T patent/TR200403498T2/xx unknown
- 2001-07-06 IS IS5993A patent/IS5993A/is unknown
- 2001-07-09 IL IL144202A patent/IL144202A/en not_active IP Right Cessation
- 2001-07-24 US US09/911,777 patent/US6869605B2/en not_active Expired - Fee Related
- 2001-07-24 NO NO20013641A patent/NO20013641L/no not_active Application Discontinuation
-
2003
- 2003-11-14 CY CY20031101083T patent/CY1107453T1/el unknown
-
2008
- 2008-11-27 JP JP2008303135A patent/JP4955642B2/ja not_active Expired - Fee Related
-
2009
- 2009-08-20 IL IL200498A patent/IL200498A0/en unknown
-
2011
- 2011-10-05 CY CY20111100946T patent/CY1112458T1/el unknown
-
2012
- 2012-01-24 JP JP2012012379A patent/JP2012087145A/ja not_active Withdrawn
- 2012-03-29 JP JP2012077812A patent/JP2012126749A/ja active Pending
- 2012-04-27 NO NO20120524A patent/NO20120524A1/no not_active Application Discontinuation
-
2014
- 2014-04-24 JP JP2014090152A patent/JP2014141527A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002535285A5 (https=) | ||
| Gridley et al. | Incidence of cancer among patients with rheumatoid arthritis | |
| HUS1600042I1 (hu) | Anti-CS1 antitestek terápiás alkalmazása | |
| JP2001515712A5 (https=) | ||
| JP2003503361A5 (https=) | ||
| WO2005102387A3 (en) | Therapeutic use of anti-cs1 antibodies | |
| JP2004501101A5 (https=) | ||
| ATE212038T1 (de) | Humanisierte monoklonale anti-cd40 antikörper und fragmente zur hemmung der b-zellaktivierung | |
| DE69734317D1 (de) | Anti-tnf antikörper / tnf rezeptor und methotrexat zur behandlung von autoimmunkrankheiten | |
| EP1245676A4 (en) | HUMANE MONOCLONAL ANTIBODIES AGAINST THE TGF-BETA II RECEPTOR AND THEIR MEDICAL USE | |
| WO2001078779A3 (en) | Antibody alpha4beta7 integrin and its use to treat inflammatory bowel disease | |
| JP2004537500A5 (https=) | ||
| ATE407149T1 (de) | Detoxifizierung durch intramuskulär verabreichte f(ab')2 fragmente | |
| Marshall et al. | Effects of coumarin (1, 2-benzopyrone) and cimetidine on peripheral blood lymphocytes, natural killer cells, and monocytes in patients with advanced malignancies | |
| US6288074B1 (en) | Method of treating lymphoproliferative syndrome | |
| WO2002026193A3 (en) | Use of cyr61 in the treatment and diagnosis of human uterine leiomyomas | |
| WO2005058966A3 (en) | Use of ligands of specific antigen for the diagnosis and treatment of solid tumours and bone-related cancerous diseases | |
| CN1208643A (zh) | 一种治疗前列腺疾病的药物及其制备方法 | |
| JPH11279199A5 (https=) | ||
| Simmons | When paradigms fall: the demise of" hit hard, hit early" | |
| Grin | Condylomata acuminata: Epidemiologie und Therapie. | |
| Nicoletti | Observations on Results Achieved in 25,000 Patients Treated with Both Acupuncture and Homeopathy | |
| RU2004121622A (ru) | Способ лечения субинволюции матки у коров | |
| Berd | Melanoma vaccines as a therapeutic option | |
| Prenen et al. | Thalidomide: een nieuwe behandelingsstrategie bij multipel myeloom |